Mangafodipir as an Adjunct to Percutaneous Coronary Intervention

NCT00966563 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Myocardial Infarction

Interventions

DRUG: Mangafodipir
DRUG: Placebo

Sponsor

Egetis Therapeutics